Loading stock data…
BioCryst Pharmaceuticals (BCRX)
$9.55-0.39 (-3.92%)
After Hours$9.55+0.00 (+0.00%)· Last close Jun 29
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
BioCryst Pharmaceuticals, Inc. in the Healthcare sector is trading at $9.55 with a market capitalization of $2.3B. Wall Street consensus targets $21.30 (10 analysts), implying a +123.0% move over the next 12 months. The stock is currently 13% below its 52-week high of $10.94, remaining 19.7% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +123.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $156.41M↓ | $406.56M↑ | $159.40M↓ | $163.35M↑ | $145.53M |
| Gross Profit | $151.04M↓ | $397.03M↑ | $157.21M↓ | $160.56M↑ | $140.97M |
| Operating Income | -$701.60M↓ | $260.38M↑ | $29.59M↓ | $29.79M↑ | $21.23M |
| Net Income | -$721.81M↓ | $245.84M↑ | $12.90M↑ | $5.08M↑ | $32,000 |
Peer Comparison
JNJUNHPFE
Fundamentals
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatme...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.27B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
82.69%
Volume
Today's trading volume
6.44M
Recent News
BioCryst to Discontinue Internal Discovery Programs, Close Birmingham Facility by Year-End
BioCryst Pharmaceuticals (BCRX) said Monday it will discontinue its internal discovery programs and
BCRX Stock Set For Best Week In Over 3 Months – Retail Shifts Focus To This Crucial Breakout Level
BCRX stock climbed past its key resistance at $10.32 to hit a record high earlier in the session, before paring most of the gains.
Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy Now?
Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on BCRX. BioCryst Pharmaceuticals, Inc.’s share was trading at $8.33 as of June 9th. BCRX’s trailing and forward P/E were 7.46 and 72.99 respectively according to Yahoo […]
BioCryst Pharmaceuticals Backs ORLADEYO Outlook as Navenibart Trial Advances
BioCryst Pharmaceuticals (NASDAQ:BCRX) CEO Charlie Gayer said the company remains on track with its commercial and development plans during a Jefferies fireside chat, highlighting continued growth expectations for hereditary angioedema drug ORLADEYO, progress for late-stage HAE candidate navenibart
BioCryst (BCRX) Is Down 6.7% After Q1 Loss And Navenibart Deal News Has The Bull Case Changed?
BioCryst Pharmaceuticals reported first-quarter 2026 results with revenue of US$156.41 million, up from US$145.53 million a year earlier, but moved from a small profit to a net loss of US$721.81 million, while maintaining full‑year revenue guidance of US$635 million to US$660 million. Alongside these results, the company entered a licensing agreement giving an Irish affiliate of Neopharmed Gentili exclusive European rights to navenibart for hereditary angioedema, bringing in US$70 million...